PFE — Pfizer Inc.
Is PFE overbought or oversold? Here is the current MarketMoodz read.
Pfizer Inc. (PFE) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Pharmaceuticals) last closed at $27.80. The rating moved from Overbought to Neutral on October 2, 2026.
- Public ratingNeutral (as of October 3, 2026)
- Last close$27.80
- Last changeMoved from Overbought to Neutral on October 2, 2026
- SectorHealthcare
- IndustryPharmaceuticals
AI analysis
Pfizer Inc. combines large-scale, diversified revenue streams with strong cash generation, supporting shareholder returns and selective investment in late-stage programs. Recent market risk-off flows favor defensive healthcare exposure, while the company’s manufacturing and commercial scale provide advantages for launches and global distribution. Growth upside is primarily tied to successful late-stage readouts, label expansions and targeted acquisitions or partnerships. However, ongoing policy-driven pricing pressure, intensified competition in high-growth therapy areas and the timing of patent expiries remain material headwinds that could limit upside if realized. Short-term price action will likely track broader risk sentiment and any news on product approvals, commercial data or policy developments.
Key factors
- Diversified global portfolio across vaccines, oncology, established therapeutics and specialty medicines provides stable revenue base and cash generation
- Sizeable free cash flow and strong balance sheet support dividends, buybacks and selective M&A or bolt-on transactions
- Late-stage pipeline and external collaborations increase probability of meaningful new product approvals and lifecycle extensions
- Defensive sector positioning and demand for healthcare assets in risk-off environments can provide relative downside protection
- Manufacturing scale and global commercial footprint enable rapid launch and scale-up for new approvals and supply reliability
Risks
- Policy and pricing pressure (Medicare negotiation, IRA-type measures) that could compress U.S. pricing and margins for high-cost drugs
- Competitive pressure from novel modalities (GLP-1 / amylin combos, next‑gen biologics) that could erode market share in growth segments
- Patent expiries and generic/biosimilar entry for legacy franchises that weigh on mid-term revenues
- Regulatory, clinical trial and approval risk for late-stage assets; clinical setbacks could depress sentiment
- Supply-chain disruptions or geopolitical shocks that affect production or global distribution
- Macro-driven risk-off market environment that can delay elective prescribing or pricing negotiations in some markets
Latest MarketMoodz coverage
- U.S. Asking Prices Post Deepest Annual Drop Since 20172026-07-01
- ADP: June Private Payrolls 98K vs 118K Estimate — Job Growth Cools2026-07-01
- Innovent, Lilly Expand Verzenios Commercialization in China2026-07-01
- Trump: TSMC Arizona Expansion Could Push U.S. to 50% of Chips2026-07-01
- Pfizer's NSCLC ADC misses OS endpoint but shows signal in earlier-line patients2026-06-23
See today's live rating, score and targets
Members see the live hourly rating for PFE — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.